Press Release

Go to Topics


Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2022
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2022 (PDF:169KB)
Announcement of Executive Change (PDF:150KB)
Declaration of Achieving Carbon Neutrality by 2040
- Contributing to the Realization of a Sustainable Society Through Initiatives to Deal with Climate Change -
Astrego Diagnostics AB Becomes Wholly-owned Sysmex Subsidiary through the Acquisition of Outstanding Shares
- Commercialization of Rapid Antimicrobial Susceptibility Test to Reinforce Structure for Promoting AMR Countermeasures - (PDF:188KB)
Sysmex Employee to Receive “Medal with Purple Ribbon” in Spring 2022 Medal of Honor Awards (PDF:185KB)
Sponsorship of the Thematic Project “Amplification of Lives” of Expo 2025, Osaka, Kansai, Japan
Announcement of Organizational and Personnel Changes (PDF:117KB)
Sysmex Forms Capital and Business Tie-up with KAINOS Laboratories to Drive Growth in the Immunochemistry Field
- Deepening Alliance in Reagent Development/Production to Create a Win-Win Situation - (PDF:180KB)
Sysmex Establishes Subsidiary in Saudi Arabia
- Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market - (PDF:162KB)
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2022 (PDF:437KB)
Information about Termination of the Litigation against Sysmex Corporation and its Subsidiary (PDF:128KB)
Sysmex Files for Manufacturing and Marketing Approval for an Assay Kit that Assists in Identification of Amyloid Beta (Aβ) Accumulation in the Brain
- Measurement of Plasma Aβ Using Automated Immunoassay System HISCL™-5000/HISCL™-800 - (PDF:150KB)